Primmune Therapeutics Secures $22.5 Million Contract from Defense Threat Reduction Agency (DTRA) to Advance PRTX007 for Treatment of Lassa Fever
Primmune Therapeutics Presents Data from Phase 1 Study Evaluating PRTX007
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for the Study of Liver Diseases (AASLD) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and to clear human papillomavirus and related pre-cancerous cervical lesions, today announced that Primmune’s Senior Vice President & Chief Scientific Officer James Appleman, Ph.D., will present at the 4th STING & TLR-Targeting Therapies Summit being held in Boston, Massachusetts from May 9-11, 2023.
Primmune Therapeutics Presents New Clinical Data from Phase 1 Study Evaluating PRTX007 in Healthy Volunteers at the 2023 American Association for Cancer Research (AACR) Annual Meeting
Primmune Therapeutics to Present New Clinical Data from Phase 1 Study Evaluating PRTX007 at the 2023 American Association for Cancer Research (AACR) Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat solid tumors in the advanced cancer setting and for clearing human papilloma virus-driven pre-cancerous cervical lesions, today announced that they will present interim Phase 1 clinical data for PRTX007, a novel, orally administered, small molecule toll-like receptor 7 (TLR7) specific agonist, at the 2022 American Association for Cancer Research (AACR) Annual Meeting. The AACR annual meeting will be held in New Orleans from April 8-13. An e-poster will be made available online Friday, April 8 at 1 p.m. ET.
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today presented data evaluating the antiviral activity of PRTX007, a novel, small molecule toll-like receptor 7 (TLR7) specific agonist, at the International Conference on Antiviral Research (ICAR).
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 32nd Annual Oppenheimer Healthcare Conference, which will be held virtually March 15 to 17.
SAN DIEGO--(BUSINESS WIRE)--Primmune Therapeutics, a biotech company harnessing the power of the innate immune system to treat cancers and viral diseases, today announced that Charles McDermott, President and Chief Executive Officer of Primmune, will present at the 12th Annual Global Life Science Partnering Conference, presented by Biocom California, which will be held Feb. 22 to 24 in San Diego.